|
|
|
|
|
|
|
|
|
|
|
|
|
26.03.26 - 10:00
|
Results: SINO BIOPHARM Full-Yr NP Fades 33%; Final DPS HKD5 Cents (AAStocks)
|
|
|
SINO BIOPHARM (01177.HK) announced its 2025 annual results, reporting revenue of RMB31.834 billion, up 10.3% YoY. Profit attributable to shareholders was RMB2.343 billion, down 33% YoY, with an EPS of RMB13.02 cents. A final DPS of HKD5 cents was declared, compared to HKD4 cents in the same period last year. Including the interi......
|
|
|
05.03.26 - 05:30
|
Midday Takeaway: HSI Closes Midday at 25,462, Up 212 pts; HSTI Closes Midday Flat at 4,829; SINO BIOPHARM Up over 5%; KINETIC DEV Hit New Highs (AAStocks)
|
|
|
At midday close, HSI rose 212 pts or 0.8% to 25,462. HSTI stayed still at 4,829. HSCEI gained 20 pts or 0.2% to 8,504.Active Heavyweights:MEITUAN (03690.HK) closed at $74.1, down 1.7%XIAOMI (01810.HK) closed at $32.5, up 1.6%HKEX (00388.HK) closed at $410.4, up 1.4%BABA (09988.HK) closed at $128.4, down 1.2%TENCENT (00700.HK) cl......
|
|
|
|
|
04.03.26 - 10:36
|
China outlicensing tops US$52 billion in first 2 months on rise in global deals (SCMP)
|
|
|
The pace and size of outlicensing deals between Chinese drug makers and global partners have accelerated this year, highlighted by two agreements announced this week, each worth more than US$1 billion.
The string of deals shows how China is becoming a sought-after source of drug candidates for multinational pharmaceutical companies, which are increasingly looking for long-term partnerships rather than one-off arrangements, analysts said.
The latest deals, Sino Biopharmaceutical's agreement with......
|
|
|
|
|
|
|
|
|
22.01.26 - 19:18
|
Sino Biopharma CEO on China′s Clinical Trial Growth (Bloomberg)
|
|
|
Sino Biopharmaceutical CEO Eric Tse discusses the "survival" necessity of China's rapid clinical trial growth and his open-ended approach to deals in 2026. He speaks to Bloomberg TV's Haslinda Amin on the sidelines of the 2026 World Economic Forum in Davos, Switzerland. (Source: Bloomberg)...
|
|
|
14.01.26 - 06:18
|
Sino Biopharm To Remain Active in M&A, Says Chair (Bloomberg)
|
|
|
Sino Biopharmaceutical Chairwoman Theresa Tse says her company is open to acquiring more biotech companies in China after announcing a new buyout. She also tells "Bloomberg: The China Show" that the company is looking for partnerships with bigger multinational firms. (Source: Bloomberg)...
|
|
|
|
|
13.01.26 - 05:45
|
Research: CMBI Ratings, TPs on Pharma (Table) (AAStocks)
|
|
|
Shares | Ratings | Target prices (HK$)3SBIO(01530.HK) | Buy | 37.58 GUSHENGTANG(02273.HK) | Buy | 44.95 SINO BIOPHARM(01177.HK) | Buy | 9.4 WUXI XDC(02268.HK) | Buy | 74 ~AAStocks Financial NewsWeb Site: www.aastocks.com...
|
|
|
|
|
23.12.25 - 03:15
|
Research: CMBI Ratings, TPs on Pharmas (Table) (AAStocks)
|
|
|
Shares | Ratings | Target prices (HK$)3SBIO(01530.HK) | Buy | 37.58 GUSHENGTANG(02273.HK) | Buy | 44.95 WUXI XDC(02268.HK) | Buy | 74 SINO BIOPHARM(01177.HK) | Buy | 9.4 ~AAStocks Financial NewsWeb Site: www.aastocks.com...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
